{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:23:25Z","timestamp":1790796205176,"version":"4.1.0"},"reference-count":34,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,3,3]],"date-time":"2024-03-03T00:00:00Z","timestamp":1709424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Assessing minimal residual disease (MRD) in B\u2010cell precursor acute lymphoblastic leukaemia (BCP\u2010ALL) is essential for adjusting therapeutic strategies and predicting relapse. Quantitative polymerase chain reaction (qPCR) is the gold standard for MRD. Alternatively, flow cytometry is a quicker and cost\u2010effective method that typically uses leukaemia\u2010associated immunophenotype (LAIP) or different\u2010from\u2010normal (DFN) approaches for MRD assessment. This study describes an optimized 12\u2010colour flow cytometry antibody panel designed for BCP\u2010ALL diagnosis and MRD monitoring in a single tube. This method robustly differentiated hematogones and BCP\u2010ALL cells using two specific markers: CD43 and CD81. These and other markers (e.g. CD73, CD66c and CD49f) enhanced the specificity of BCP\u2010ALL cell detection. This innovative approach, based on a dual DFN\/LAIP strategy with a principal component analysis method, can be used for all patients and enables MRD analysis even in the absence of a diagnostic sample. The robustness of our method for MRD monitoring was confirmed by the strong correlation (<jats:italic>r<\/jats:italic>\u2009=\u20090.87) with the qPCR results. Moreover, it simplifies and accelerates the preanalytical process through the use of a stain\/lysis\/wash method within a single tube (&lt;2\u2009h). Our flow cytometry\u2010based methodology improves the BCP\u2010ALL diagnosis efficiency and MRD management, offering a complementary method with considerable benefits for clinical laboratories.<\/jats:p>","DOI":"10.1111\/bjh.19390","type":"journal-article","created":{"date-parts":[[2024,3,3]],"date-time":"2024-03-03T23:00:17Z","timestamp":1709506817000},"page":"1872-1881","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Faster clinical decisions in B\u2010cell acute lymphoblastic leukaemia: A single flow cytometric 12\u2010colour tube improves diagnosis and minimal residual disease follow\u2010up"],"prefix":"10.1111","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4890-336X","authenticated-orcid":false,"given":"Benjamin","family":"Lebecque","sequence":"first","affiliation":[{"name":"H\u00e9matologie Biologique, CHU Clermont\u2010Ferrand, Estaing  Clermont\u2010Ferrand France"},{"name":"Equipe d'Accueil EA7453 CHELTER Universit\u00e9 Clermont Auvergne  Clermont\u2010Ferrand France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joevin","family":"Besombes","sequence":"additional","affiliation":[{"name":"H\u00e9matologie Biologique, CHU Clermont\u2010Ferrand, Estaing  Clermont\u2010Ferrand France"},{"name":"Equipe d'Accueil EA7453 CHELTER Universit\u00e9 Clermont Auvergne  Clermont\u2010Ferrand France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis\u2010Thomas","family":"Dannus","sequence":"additional","affiliation":[{"name":"H\u00e9matologie Biologique, CHU Clermont\u2010Ferrand, Estaing  Clermont\u2010Ferrand France"},{"name":"Equipe d'Accueil EA7453 CHELTER Universit\u00e9 Clermont Auvergne  Clermont\u2010Ferrand France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"De\u00a0Antonio","sequence":"additional","affiliation":[{"name":"Unit\u00e9 de Biostatistiques, Direction de la Recherche Clinique et de l'Innovation Centre Hospitalier Universitaire de Clermont\u2010Ferrand, Universit\u00e9 Clermont Auvergne  Clermont\u2010Ferrand France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Cacheux","sequence":"additional","affiliation":[{"name":"Service de Th\u00e9rapie Cellulaire et H\u00e9matologie Clinique Adulte  Clermont\u2010Ferrand France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Gr\u00e8ze","sequence":"additional","affiliation":[{"name":"CHU Clermont\u2010Ferrand, Service H\u00e9matologie Oncologie P\u00e9diatrique, H\u00f4pital Estaing  Clermont\u2010Ferrand France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Montagnon","sequence":"additional","affiliation":[{"name":"H\u00e9matologie Biologique, CHU Clermont\u2010Ferrand, Estaing  Clermont\u2010Ferrand France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Veronese","sequence":"additional","affiliation":[{"name":"Equipe d'Accueil EA7453 CHELTER Universit\u00e9 Clermont Auvergne  Clermont\u2010Ferrand France"},{"name":"Cytog\u00e9n\u00e9tique M\u00e9dicale, CHU Clermont\u2010Ferrand, CHU Estaing  Clermont\u2010Ferrand France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Tchirkov","sequence":"additional","affiliation":[{"name":"Equipe d'Accueil EA7453 CHELTER Universit\u00e9 Clermont Auvergne  Clermont\u2010Ferrand France"},{"name":"Cytog\u00e9n\u00e9tique M\u00e9dicale, CHU Clermont\u2010Ferrand, CHU Estaing  Clermont\u2010Ferrand France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9438-621X","authenticated-orcid":false,"given":"Olivier","family":"Tournilhac","sequence":"additional","affiliation":[{"name":"Equipe d'Accueil EA7453 CHELTER Universit\u00e9 Clermont Auvergne  Clermont\u2010Ferrand France"},{"name":"Service de Th\u00e9rapie Cellulaire et H\u00e9matologie Clinique Adulte  Clermont\u2010Ferrand France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1858-0587","authenticated-orcid":false,"given":"Marc G.","family":"Berger","sequence":"additional","affiliation":[{"name":"H\u00e9matologie Biologique, CHU Clermont\u2010Ferrand, Estaing  Clermont\u2010Ferrand France"},{"name":"Equipe d'Accueil EA7453 CHELTER Universit\u00e9 Clermont Auvergne  Clermont\u2010Ferrand France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Veyrat\u2010Masson","sequence":"additional","affiliation":[{"name":"H\u00e9matologie Biologique, CHU Clermont\u2010Ferrand, Estaing  Clermont\u2010Ferrand France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,3,3]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404586"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2018.03.005"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1070153"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.10.008"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-553X.2010.01254.x"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP02RPVOKTNWEC"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.12795"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.20440"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21865"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-07-726307"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21831"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04580-2"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-61779-074-4_8"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05374.x"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002132"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004043"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2022.04.014"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21482"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.22104"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21486"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21528"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.22043"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013626"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpcy.73"},{"key":"e_1_2_9_27_1","unstructured":"Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research.Hematologic malignancies: regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment.2020. US Food and Drug Administration. Available from:https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/hematologic\u2010malignancies\u2010regulatory\u2010considerations\u2010use\u2010minimal\u2010residual\u2010disease\u2010development\u2010drug\u2010and"},{"key":"e_1_2_9_28_1","unstructured":"HeymanM.ALLTogether1 \u2010 A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0\u201345\u2009Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL).2024. Available from:https:\/\/clinicaltrials.gov\/study\/NCT04307576"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21239"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017003"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V76.10.1908.bloodjournal76101908"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20012066"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1385\/IR:25:2:155"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0242"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-169040"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.19390","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T08:43:53Z","timestamp":1730709833000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.19390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,3]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1111\/bjh.19390"],"URL":"https:\/\/doi.org\/10.1111\/bjh.19390","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,3]]},"assertion":[{"value":"2024-01-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}